Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P62308
UPID:
RUXG_HUMAN
Alternative names:
Sm protein G
Alternative UPACC:
P62308; D6W5G6; Q15357; Q6IB86
Background:
Small nuclear ribonucleoprotein G (Sm protein G) is a pivotal component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), essential for pre-mRNA splicing. It participates in the assembly of both pre-catalytic spliceosome B complex and activated spliceosome C complexes, facilitating the splicing of U12-type introns and playing a role in histone 3'-end processing.
Therapeutic significance:
Understanding the role of Small nuclear ribonucleoprotein G could open doors to potential therapeutic strategies.